Paratek Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q1 2012 to Q2 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Paratek Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q1 2012 to Q2 2023.
  • Paratek Pharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2023 was -186 %, a 20.5% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2023 -186 +47.9 +20.5% Jun 30, 2023
Q1 2023 -195 +56.2 +22.3% Mar 31, 2023
Q4 2022 -206 +50.4 +19.7% Dec 31, 2022
Q3 2022 -216 +48.4 +18.3% Sep 30, 2022
Q2 2022 -234 +44.4 +16% Jun 30, 2022
Q1 2022 -252 +57.4 +18.6% Mar 31, 2022
Q4 2021 -256 +122 +32.2% Dec 31, 2021
Q3 2021 -264 +218 +45.2% Sep 30, 2021
Q2 2021 -278 +306 +52.4% Jun 30, 2021
Q1 2021 -309 +471 +60.4% Mar 31, 2021
Q4 2020 -378 +1.07K +74% Dec 31, 2020
Q3 2020 -482 -12.2K -104% Sep 30, 2020
Q2 2020 -585 -1.57K -159% Jun 30, 2020
Q1 2020 -780 -1.27K -259% Mar 31, 2020
Q4 2019 -1.45K -1.73K -624% Dec 31, 2019
Q3 2019 11.7K +11.5K +5832% Sep 30, 2019
Q2 2019 985 +860 +687% Jun 30, 2019
Q1 2019 489 +415 +562% Mar 31, 2019
Q4 2018 277 +203 +274% Dec 31, 2018
Q3 2018 197 +126 +175% Sep 30, 2018
Q2 2018 125 +57.2 +84.1% Jun 30, 2018
Q1 2018 73.9 +9.06 +14% Mar 31, 2018
Q4 2017 74.2 +10.8 +17% Dec 31, 2017
Q3 2017 71.8 +18.8 +35.4% Sep 30, 2017
Q2 2017 68 +21 +44.6% Jun 30, 2017
Q1 2017 64.8 +29.3 +82.5% Mar 31, 2017
Q4 2016 63.5 +36.8 +138% Dec 31, 2016
Q3 2016 53 +32.8 +162% Sep 30, 2016
Q2 2016 47 Jun 30, 2016
Q1 2016 35.5 Mar 31, 2016
Q4 2015 26.7 Dec 31, 2015
Q3 2015 20.2 Sep 30, 2015
Q4 2012 8.11 Dec 31, 2012
Q3 2012 3.86 Sep 30, 2012
Q2 2012 4.14 Jun 30, 2012
Q1 2012 5.03 Mar 31, 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.